drugset / Trial / NCT07181239
Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the efficacy between CM336 and investigator's choice Standard of Care in relapsed or refractory multiple myeloma (RRMM) patients.
Timeline
- Start
- 2025-09
- Primary completion
- 2027-09
- Completion
- 2030-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM336 | Monoclonal antibody | — | — |